August 9, 2021

Patients with cancer have been shown to experience disparate outcomes based on socioeconomic disparities. This study, published in Hematology/Oncology and Stem Cell Therapy, sought to explore the relationship between socioeconomic status and survival outcomes among patients with multiple myeloma who were not considered for first-line hematopoietic stem cell transplant.  Data were taken from the National Cancer...

Racial minority patients have been found to utilize novel agents for multiple myeloma less often than white patients. This finding has been hypothesized to be the result of increased drug costs and socioeconomic disparities. This study, published in Clinical Lymphoma Myeloma and Leukemia, compared rates of bortezomib and lenalidomide use between Black and white patients with multiple...

In the past two decades, treatment advancements for multiple myeloma have significantly improved patient outcomes. Now, multiple lines of treatment are available, and patients enjoy greater life expectancy. However, not all patients receive treatment in a timely manner, which is needed to avoid end-organ damage. This study, published in JCO Oncology Practice, focuses on disparities in...